3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
48
Phase 1
26
Phase 1/2
25
Phase 3
5
Phase NA
2
Phase EARLY_PHASE1
2
Phase 4
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Dermatologic
1
Conditions
Skin Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Interventions
Imiquimod
15
Aminolevulinic Acid
8
Fluorouracil
6
Diclofenac
6
3-ingenyl angelate
6
Nivolumab
5
Cryotherapy
5
tirbanibulin
4
methyl 5-aminolevulinate
4
Sirolimus
4
denileukin diftitox
3
aldesleukin
3
Photochemotherapy
3
Ipilimumab
3
Blood Specimen Collection
3
relatlimab
2
Vemurafenib
2
Tacrolimus
2
Prednisone
2
Ointments
2
Methotrexate
2
Immune Checkpoint Inhibitors
2
HhAntag691
2
Gels
2
Cyclosporine
2
Cryosurgery
2
trametinib
1
technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran
1
technetium Tc 99m nanocolloid
1
sargramostim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Interleukin-2
×
Dermatologic
×
Clear all
NCT01856023
2023-12-05
PROCLIVITY02
Clinigen, Inc.
Phase 4
Terminated
29 enrolled
9 charts